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Abstract
Background: There is currently insufficient evidence for the clinical and cost-effectiveness of psychological
therapies for treating post-stroke depression.
Methods/Design: BEADS is a parallel group feasibility multicentre randomised controlled trial with nested
qualitative research and economic evaluation. The aim is to evaluate the feasibility of undertaking a full trial
comparing behavioural activation (BA) to usual stroke care for 4 months for patients with post-stroke depression.
We aim to recruit 72 patients with post-stroke depression over 12 months at three centres, with patients identified
from the National Health Service (NHS) community and acute services and from the voluntary sector. They will be
randomly allocated to receive behavioural activation in addition to usual care or usual care alone. Outcomes will be
measured at 6 months after randomisation for both participants and their carers, to determine their effectiveness.
The primary clinical outcome measure for the full trial will be the Patient Health Questionnaire-9 (PHQ-9). Rates of
consent, recruitment and follow-up by centre and randomised group will be reported. The acceptability of the
intervention to patients, their carers and therapists will also be assessed using qualitative interviews. The economic
evaluation will be undertaken from the National Health Service and personal social service perspective, with a
supplementary analysis from the societal perspective. A value of information analysis will be completed to identify
the areas in which future research will be most valuable.
Discussion: The feasibility outcomes from this trial will provide the data needed to inform the design of a
definitive multicentre randomised controlled trial evaluating the clinical and cost-effectiveness of behavioural
activation for treating post-stroke depression.
Trial registration: Current controlled trials ISRCTN12715175
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Background
Depression is the most commonly investigated emotional
consequence of stroke [1] with an average prevalence of
29 %, which remains consistent up to 10 years post-stroke
[2]. Effective treatment of depression is important because
depression is associated with increased healthcare utilisation
[3], worse rehabilitation outcomes [4–7], increased carer
strain [8] and increased mortality [2, 9]. Co-morbid long-
term physical health conditions and mental health problems
have been found to increase health care costs [10]. Stroke
patients who are depressed may engage less in rehabilitation,
which in turn can lead to decreased functional recovery [7].
Post-stroke depression is also associated with lower quality
of life [2, 11]. Thus, in addition to improving mood, effective
treatment of post-stroke depression is important because it
has the potential to improve patients’ functional outcomes
and quality of life and also reduce strain on their carers.
About one third of stroke patients have aphasia [12, 13] and
approximately 70 % will have cognitive impairment [14, 15].
Aphasia can affect all communication modalities including
speaking, understanding, reading and writing. Stroke survi-
vors with aphasia may be particularly susceptible to post-
stroke depression [16, 17].
There is currently insufficient evidence for the clinical
and cost-effectiveness of psychological therapies for tre-
ating post-stroke depression [18]. Trials of brief psy-
chosocial behavioural intervention plus antidepressant
[19] and motivational interviewing [20, 21] reduced post-
stroke depression but these studies recruited patients early
after stroke and excluded those with severe communica-
tion or cognitive problems, so these findings may not be
applicable to all patients with post-stroke depression.
There is evidence from single-case design studies that
some patients with post-stroke depression improve follow-
ing cognitive behavioural therapy (CBT) [22, 23]. How-
ever, the only randomised controlled trial of CBT for post-
stroke depression found no significant difference between
those patients who received CBT, an attention placebo or
usual care [24].
A psychological intervention which may be suitable
for stroke patients is behavioural activation (BA) ther-
apy. BA is based on the behavioural model of depression,
where depression is believed to result from a lack of
response-contingent positive reinforcement [25]. Positive
reinforcement is dependent on the person’s actions [26]
and reduction in activity can lead to loss of reinforcement.
Stroke can result in a loss or restriction of rewarding
activities and interactions (such as everyday activities,
hobbies and social interactions) and this loss may lead to
depression. BA aims to increase activity level, particularly
the frequency of pleasant events, to improve mood. BA is
effective at treating depression in adults in primary care
settings, older adults and patient/carer dyads with demen-
tia, and has comparable effectiveness to CBT [27–32].
A multicentre randomised controlled trial, the
Communication and Low Mood: CALM trial [33] (n = 105)
evaluated BA, delivered by an assistant psychologist,
for treating low mood in stroke patients with aphasia.
This found that mood was significantly better at 6-month
follow-up in those who received BA compared to usual
clinical care. The transferability of BA to hard-to-reach
populations, such as those with aphasia and severe cogni-
tive problems [34, 35], adds to its potential as a psycho-
logical intervention after stroke. Given that the CALM
trial demonstrated that it was possible to deliver BA to a
group of patients usually excluded from psychological in-
terventions, there is significant potential for using BA for
treating all stroke patients with depression.
However, as the CALM trial was not conducted with
the wider stroke population, a more robust pilot study is
now required to inform any future proposal for a defini-
tive multicentre randomised controlled trial (RCT) evalu-
ating the clinical and cost-effectiveness of BA for treating
post-stroke depression [36–38]. Therefore, the BEADS
trial is looking at the feasibility of delivering BA to all
patients with post-stroke depression and the feasibility of
proceeding to a definitive trial. This study will provide
information on feasibility and clinical outcomes of BA for
treating post-stroke depression and its acceptability to
patients, carers and therapists. The results of this study
will also provide data on the feasibility of delivering the
BA intervention in the National Health Service (NHS) as
part of routine clinical practice.
Objectives
The overarching aim of the BEADS trial is to explore the
feasibility of a study to investigate the clinical and cost-
effectiveness of behavioural activation therapy for people
with post-stroke depression. The primary objective is to
determine the feasibility of proceeding to a definitive trial,
based on
a. Feasibility of recruitment to the main trial
b. Acceptability of the research procedures and measures
c. Appropriateness of the baseline and outcome
measures for assessing impact
d. Retention of participants at outcome
e. Potential value of conducting the definitive trial,
based upon value of information analysis
The secondary objective is to determine the feasibility
of delivering the behavioural activation therapy interven-
tion with patients with post-stroke depression, based on
a. Acceptability of behavioural activation therapy to
participants, carers and therapists
b. Feasibility of delivering the intervention by assistant
psychologists or low-intensity psychological
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wellbeing practitioners under the supervision of an
experienced mental health practitioner
c. Documentation of ‘usual care’ using a healthcare
resource use questionnaire
d. Treatment fidelity of the behavioural activation
therapy
e. Feasibility of delivery of behavioural activation
therapy within current services and within a
definitive trial
f. Estimate the sample size required for the main RCT
Methods/Design
BEADS is a parallel group feasibility multicentre ran-
domised controlled trial design, with nested qualitative re-
search, comparing behavioural activation therapy to usual
stroke care for patients with post-stroke depression.
Setting and participants
Participants will be recruited from three centres (Sheffield,
Derby, and Mansfield). Participants will be identified
through NHS hospital stroke databases, community stroke
team databases, hospital stroke wards, caseloads of com-
munity and acute stroke teams and the voluntary sector
(stroke and aphasia groups).
Participants will be included in the study if they
1. Have a diagnosis of ischaemic or haemorrhagic
stroke
2. Are aged 18 years or over
3. Are living in community settings (including nursing
homes)
4. Are a minimum of 3 months and a maximum of
5 years post-stroke and
5. Are identified as depressed. Depression is defined
in two ways:
a. For participants who are able to complete the
Patient Health Questionnaire-9 (PHQ-9 [39]):
a score of ≥10 on the PHQ-9, or;
b. For participants with communication difficulties
or severe cognitive difficulties who are unable to
complete the PHQ-9: a score of at least 50/100 on
Visual Analog Mood Scales (VAMS) Sad item [40]
Participants will be excluded from the study if they
1. Had a diagnosis of dementia prior to the stroke
(based on self-report by patient/carer)
2. Were receiving medical or psychological treatment
for depression at the time at which they had their
stroke (based on self-report by patient/carer)
3. Are currently receiving psychological intervention
4. Have communication difficulties that would impact
on their capacity to take part in the intervention
(based on assessment with the Consent Support
Tool [41] for people with aphasia)
5. Have visual or hearing impairments that would
impact on their capacity to take part in the
intervention (based on the therapist’s discretion at
baseline assessment)
6. Were unable to communicate in English prior to the
stroke or do not have mental capacity to consent to
take part in the trial.
The criteria are designed to identify those who would
be suitable for the intervention were it to be offered
within clinical practice. All reasons for patient exclusion
will be recorded.
Recruitment
The specific process for recruitment will vary according
to where the participant is recruited from. Clinical teams
will send invitation letters to those on the hospital or
community stroke databases of discharged patients.
Patients will be sent a postal pack containing a covering
letter, participant information sheet, reply slip, PHQ-9,
VAMS Sad and prepaid envelope. Patients who are inter-
ested in taking part will return the completed PHQ-9
and VAMS Sad with the reply slip and this will be taken
as implied consent to subsequent contact by the therap-
ist. Those who are identified as not being depressed will
be contacted by the therapist to be thanked for their
interest and will be informed that they are not eligible.
People who score as depressed but decline to participant
or are identified as not meeting the remainder of the
inclusion criteria then they would be advised to contact
their GP. The therapist will contact patients classified as
depressed to arrange a visit to check the participant
meets the remainder of the inclusion criteria, to explain
the study and formally invite those who are eligible to
take part. At this point, they will also obtain informed
consent and complete baseline assessments.
Alternatively, research nurses will visit hospital stroke
wards, and members of the community and acute stroke
teams will be asked to identify potential participants and
seek their permission to be contacted by the research
team. The therapist at each centre will also seek permis-
sion to attend stroke and aphasia groups in their locality
to explain the study to group members in order to iden-
tify potential participants. Willing patients will then be
contacted by phone to tell them more about the research
and arrange a home visit during which they will
complete the screening measures, or they can request a
postal recruitment pack. During the home visit (or by
post), those patients who are identified as not being
depressed will be thanked for their interest and will be
informed that they are not eligible. For patients who are
classified as depressed, the therapist will either (a)
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arrange a subsequent home visit or (b) continue with
recruitment of the participant. Informed consent will be
taken from eligible patients, who can then be entered
into the study and randomised accordingly (See Fig. 1).
Self-referrals will be facilitated by advertising the study
in newsletters of relevant charities and societies. Posters
will also be displayed in local voluntary sector groups,
libraries and local community centres so that potential
participants can contact the local research team. The
methods of identifying potential participants have been
kept broad to allow assessment of the optimum recruit-
ment strategy for the definitive study.
Carers of trial participants will be recruited via the
trial participants during the initial home visit. They will
be asked to complete the baseline and 6-month outcome
assessment questionnaires.
Randomisation and blinding
Participants will be randomised at baseline (after informed
consent and baseline assessments) in equal proportions to
BA or usual stroke care. Several clinical assessments will be
taken at baseline: socio-demographic and stroke character-
istics; Frenchay Aphasia Screening Test [42]—to assess
communication difficulties; Montreal Cognitive Assessment
[43]—to screen for cognitive impairment; and the Modified
Rankin Scale [44]—to assess overall disability. These mea-
sures will be used to describe the baseline characteristics of
the recruits.
Randomisation will be stratified by centre and will be
conducted using a computer-generated pseudo-random list
with random permuted blocks of varying sizes, on a re-
mote, secure internet-based randomisation system created
and hosted by the Sheffield Clinical Trials Research Unit
Fig. 1 Flow of participants through the trial
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(CTRU). Once a participant has consented to the study, the
therapist will log into the randomisation system and enter
basic demographic information. After this information has
been entered, the allocation for that participant will then be
revealed to the therapist. Access to the allocation sequence
will be restricted to those with authorisation. The sequence
of treatment allocations will be concealed until interven-
tions have been assigned and recruitment, data collection
and analyses are complete.
It is not possible pragmatically for the participant or
therapist to be blind to the group allocation, but the re-
searcher completing 6-month outcome assessments will
be blinded and will also have had no involvement in any
other aspects of the trial. The researcher will be asked to
record whether or not they think they were unblinded
and will also be asked to guess the group allocation. We
will follow guidelines to minimise unblinding during
randomised controlled trials of rehabilitation [45, 46].
Ethical issues
The trial will be conducted in accordance with the eth-
ical principles that have their origin in the Declaration
of Helsinki, 1996; the principles of Good Clinical Practice,
and the Department of Health Research Governance
Framework for Health and Social Care, 2005. Participants
will not be paid to participate in the trial. Ethical approval
to conduct the study was granted by the National Research
Ethics Service Committee for East Midlands—Leicester (ref
15/EM/0014). Local NHS Research and Development ap-
provals have also been given for each participating centre.
All trial staff and investigators will endeavour to protect the
rights of the trial’s participants to privacy and informed
consent and will adhere to the Data Protection Act, 1998.
Informed consent
Written informed consent will be obtained from all partici-
pants who are able to give it. Those who lack the mental
capacity to give consent are excluded from the trial. The
therapists will explain the details of the trial and provide a
participant information sheet, ensuring that the participant
has sufficient time to consider participating or not. Informed
consent to participate in the trial will be taken before partici-
pants undergo any interventions relating to the study. For
patients who are physically unable to sign the form (e.g.
weakness in dominant hand due to stroke) then consent will
be given using a mark or line in the presence of an inde-
pendent witness (who has no involvement in the trial) who
will then corroborate by signing the consent form.
A significant proportion (up to 50–80 %) of the stroke
population have some degree of cognitive or language
impairment—aphasia. The level of support required to
enable a person with aphasia to provide informed consent
is dependent upon the severity and profile of the aphasia.
In order to provide information in a format consistent
with each individual’s language ability, a Consent Support
Tool (CST) [41] will be used. The therapist will request
verbal consent from the potential participant to carry out
part A of the CST to determine how appropriate it is to
provide the accessible information sheet. If the CST indi-
cates that the potential participant understands less than
two key written or spoken words in a sentence, they are
likely to find it difficult to understand all the information
required to provide informed consent. These participants
will be thanked for their time but are not eligible for the
study as, despite the intervention using techniques to sup-
port the inclusion of those people with reduced language
or cognition, the intervention does rely on achieving
understanding with support and actively participating in
therapeutic communication.
The accessible information sheet will be provided to
those who understand at least two key written and spoken
words. This follows standard aphasia-friendly principles
with one idea presented per page in short simple sentences
in large font. Keywords are emboldened and each idea is
represented by a pictorial image to support understanding
of what the study is about. The therapists will be trained to
support understanding further by reading parts of the infor-
mation aloud and using supportive gestures/actions.
Once the potential participant has been given the infor-
mation and had sufficient time to ask questions and dis-
cuss with family or friends, the therapist will check the
individual has capacity to provide informed consent by
checking that they understand the information, that they
can remember what the study is about and clearly express
their decision in the way in which they usually comm-
unicate (speaking, writing, using a communication aid).
Participants with capacity to provide informed consent
who have used the accessible information provision will
be provided with an aphasia-friendly consent form and
asked to initial all boxes before signing. Where stroke
symptoms prevent initialling of boxes or providing written
consent, the patient will use a mark or line and a relative/
friend should be asked to witness the fact that the part-
icipant is consenting to the study and sign and date the
consent form to confirm this on behalf of the participant.
Written informed consent will also be taken from carer
and therapist participants for the outcome assessments
and qualitative interviews. Should there be any subsequent
amendment to the final protocol, which might affect a
participant’s participation in the trial, continuing consent
will be obtained using an amended consent form that will
be signed by the participant.
Participants have the right to withdraw from the study
at any time. Individuals removed from active participation
in the intervention will not be replaced. Reason for with-
drawal from the intervention, if known, will be recorded.
Participants may be withdrawn from the trial either at
their own request or at the discretion of the investigator.
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The investigator may withdraw a participant in the interest
of the participant or due to a deviation from the protocol.
Participants may discontinue their allocated intervention or
withdraw from the study for the following reasons: with-
drawal of consent; changes to their health status preventing
their continued participation or failure to adhere to proto-
col requirements. The participants will be made aware that
this will not affect their current or future care. Participation
in the study does not mean that access to other services,
which are part of usual care, will be compromised.
More specifically, if during the trial there is a patient
allocated to the BEADS intervention who subsequently
needs clinical psychology input (as per the protocol of
the local service) then the BEADS therapist (AP/PWP)
will discuss this with the clinical psychologist or clinical
lead and the patient and will agree what is best for the
patient. If it is agreed that the patient needs immediate
clinical psychology input then they would be withdrawn
from the BEADS intervention and they will see the clin-
ical psychologist, or be referred to alternative provision,
as appropriate to that patient. The patient will be with-
drawn from the intervention but not the overall trial, i.e.
we will still be able to collect outcome data from them.
We will record the number of patients who we withdraw
from the BEADS intervention because of a conflict with
clinical services.
Trial treatment and regimen
Intervention arm—behavioural activation therapy
Behavioural activation (BA) therapy is a structured and
individualised treatment which aims to increase people’s
level of activity, particularly the frequency of pleasant or
enjoyable events, in order to improve mood. Participants
randomised to receive BA will be treated at their place
of residence by an assistant psychologist at two centres or
low-intensity psychological wellbeing practitioner (PWP)
at one centre. They will be offered a maximum of 15 ses-
sions of BA over 4 months, with an expected average of
10 sessions. Therapy sessions will be delivered face to face
on an individual basis, at the participants’ residences and
will last about 1 h. A BA treatment manual was developed
for CALM based on the behavioural component of CBT
for depression in stroke patients [22, 24], behavioural ther-
apy with older people [47] and guidelines on conducting
therapy with people who have aphasia [35, 47, 48]. For this
trial, this therapy manual will be further revised to cover
BA with stroke patients who do not have aphasia and will
provide examples and practical guidance relevant to all
stroke patients.
The intensity and duration of therapy is based on a study
of CBT with stroke patients [24] and is informed by the
CALM study in which participants received an average of
nine 1-h sessions over 3 months [33]. Experience and criti-
cism of the CBT trial [24] was that therapy was too short.
The trial of BA for treating depression in primary care
provided 12 sessions over 3 months [49] but this was not in
a stroke sample and patients with communication and/or
cognitive difficulties may require a longer duration of ther-
apy. The duration of therapy has been increased from 3 to
4 months because the CALM study showed that it was
difficult to complete sessions in 3 months due to non-
availability of the participant and short-term illness. Extend-
ing therapy to 4 months will also allow flexibility to provide
therapy visits to support maintenance, as might be provided
in clinical practice. The number of therapy sessions will
vary according to the needs of the individual and their pro-
gress in therapy. The intensity of treatment will be negoti-
ated between the therapist and the participant, based on
their progress in achieving their therapy goals.
Goals set during treatment to increase enjoyable activities
will be tailored to the individual. BA also includes between-
session tasks to practice exercises and increase activity
levels. Behavioural treatment strategies focus on maximis-
ing mood-elevating activities. The process of BA involves
identifying how the person currently spends their time,
identifying activities that they would enjoy doing (this may
include resuming previous activities, increasing current
activity levels or introducing new activities) and setting
goals to increase the number of enjoyable activities.
The BEADS therapy manual presents a programme of
BA delivered across 10 sessions, although the number of
therapy sessions that a participant has (up to a maximum
of 15) will vary according to the needs of the individual,
their progress in therapy and their abilities.
Session 1: Introducing behavioural activation therapy
for depression after stroke
Session 2: Identifying and agreeing therapy goals
Session 3: Monitoring activity levels
Session 4: Identifying enjoyable activities
Session 5: Activity scheduling: enjoyable activities
Session 6: Activity scheduling: increasing activity levels
Session 7: Activity scheduling and increasing enjoyable
activities: problem solving
Session 8: Reviewing previous goals and setting new goals
Session 9 Generalising behavioural activation strategies
Session 10: Reviewing skills and making plans
Behavioural therapy techniques in the BEADS therapy
manual include
Activity monitoring: Identifying how participants spend
their time to assess current activity level, what activities
they enjoy and when activities could be carried out. Partici-
pants are given an activity diary or timetable to complete as
a between session task. The complexity of the diary will
vary according to the cognitive and communication abilities
of the patient and will be available in a range of formats.
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Activity scheduling: Planning in advance realistic activ-
ities and goals for the participant to complete each day,
which increases the likelihood that activities will be
carried out. The intention is to gradually increase activ-
ities, and therefore the amount of positive reinforcement
received, in order to improve mood. Activities will be set
according to the abilities and goals of the individual.
Graded task assignment: Breaking a large task into
smaller, manageable steps provides the opportunity to prac-
tise tasks participants find difficult. For example, for some-
one who wants to go shopping, they would start by going
to a familiar local shop where they know people already;
this would then be extended to going to a larger shop
which is further away.
At two of the study sites, the therapists will be an NHS
employed assistant psychologist. These are psychology
graduates who work under the supervision of a clinical
psychologist. At the third study site, the therapist will be a
low-intensity psychological wellbeing practitioner who will
have completed an accredited postgraduate certificate to
qualify them as a psychological wellbeing practitioner. The
therapists will attend a 2-day training workshop on BA led
by an NHS consultant clinical psychologist and the chief
investigator. The workshop will also include training from a
speech and language therapist on communicating with
stroke patients with cognitive and/or communication diffi-
culties. Weekly clinical supervision for the therapists will be
provided by a local clinical psychologist at each centre. In
addition, the therapists will have a monthly teleconference
with the chief investigator and NHS clinical psychologist.
Control arm—usual care
Participants in the usual care group will follow the
current care pathway. Participants will receive all other
services routinely available to them as local practice but
will have no contact with the trial therapist. This group
is the control arm and their care will be recorded to
document usual care to inform the design of the def-
initive trial. Stroke survivors are admitted to hospital,
usually to a stroke unit. On discharge, they may receive
input from an early supported discharge team or input
from a community stroke or rehabilitation team. Avail-
ability of psychological support in the community is
inconsistent and likely to vary widely across the country
as highlighted by the Stroke Improvement Programme
[50]. The CALM trial [33] found that at the 3-month
follow-up, only 14 % of participants had received mental
health treatment in the past 3 months (from a mental
health nurse, counsellor, psychologist or psychiatrist)
and this decreased to 10 % at the 6-month follow-up.
Although Improving Access to Psychological Therapies
(IAPT) have extended their remit to include people with
physical health problems [51, 52] the current rate of
uptake by stroke patients is unknown.
Only patients not currently receiving psychological
intervention are eligible to be recruited to BEADS. The
provision of clinical psychology varies. Some sites have a
full-time clinical psychologist providing input to both
hospital and community services and other sites can
access this service but do not have dedicated provision.
IAPT services will consider treating stroke patients if
referred, but this rarely occurs. GPs may prescribe anti-
depressants. Only those with severe mental health prob-
lems are referred to psychiatrists. The content of usual
care is decided locally by the clinical team as to what
this will be, as per local services.
Intervention fidelity
To ensure the fidelity of the intervention, the content of
treatment will be described and analysed. This will be
achieved by video recording up to 24 intervention sessions,
eight at each of the three centres. Participants and sessions
will be selected iteratively using purposive sampling to
represent the range of severity of depression (mild, mo-
derate, severe from baseline scores) and across the phases
of therapy (beginning, middle and end). Practices for video
recording will draw upon guidance on minimising intru-
siveness of the recording [53, 54]. The assessors analysing
the videos will apply a customised therapy record form
designed to capture a variety of key elements spanning all
aspects of the intervention. Should a participant decline
video recording, they will be offered audio recording
instead. Participants will not be excluded from the study if
they do not want to be video or audio recorded.
The therapists will also keep treatment notes for each
session to summarise the content of the intervention,
and to record goals set during BA and whether these
were achieved. Therapists will also complete a record
form of therapy content per session. The record form
will quantify the content of the intervention (for ex-
ample, how much time in each session was spent on
different components). The record form will be based
on a time sampling sheet adapted from that used in the
CALM study and based on the content of the BA man-
ual for this study. There will be triangulation between
the videos, therapy record form and manual.
Qualitative interviews will be conducted with 16 par-
ticipants (eight per arm), 10 carers (five per arm), and all
three therapists by an independent researcher to provide
a description of the acceptability of the design and pro-
cedures used in the trial and the BA intervention. All
participants who participate in an interview will provide
informed consent to do so. Participants will be selected
iteratively using purposive sampling to represent part-
icipants from all three centres, the range of severity of
depression (from baseline scores) and representation of
stroke survivors with and without aphasia. All interviews
will be audio recorded.
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Patient-centred outcomes
In addition to the feasibility outcomes, the primary clinical
outcome measure at 6 months is the PHQ-9 [39]. For
those participants with moderate to severe language prob-
lems who are unable to complete the PHQ-9, the Visual
Analog Mood Scales (VAMS) Sad item [40] will be
used—this is a single-item visual analog mood measure.
The number of participants unable to complete the PHQ-
9 will be recorded, and the VAMS Sad will be completed
with all participants so the relationship between the two
measures can be explored.
The following measures will also be used to assess
outcomes at 6 months:
 Stroke Aphasic Depression Questionnaire—Hospital
version (observer-rated depression) [55]
 Nottingham Leisure Questionnaire (leisure activities)
[56]
 Nottingham Extended Activities of Daily Living
(functional outcome) [57]
 Carer Strain Index (carer-rated level of strain) [58]
 EuroQol EQ5D (health-related quality of life)—standard
version [59] and picture-based version intended to be
accessible for people with cognitive problems [60] for
patients and carers (and proxy version)
 Healthcare resource use questionnaire
Sample size calculation
As a feasibility study, this is not powered for efficacy and
no formal interim analyses of efficacy are planned. Rather,
the sample size for a feasibility study should be adequate
to estimate the uncertain critical parameters (standard
deviation for continuous outcomes; consent rates, event
rates, attrition rates for binary outcomes) needed to in-
form the design of the definitive RCT with sufficient
precision. The sample size of 60 patients allows standard
deviation for continuous outcomes, such as the PHQ-9
and VAMS Sad, to be estimated to within precision of
approximately ±19 % of its true value (with 95 % confi-
dence). Allowing for 15 % attrition by 6-month post-
randomisation follow-up, 72 participants need to be re-
cruited. To achieve the target sample size of 72, over the
12-month recruitment period, with three centres we need
to randomise two participants per centre per month.
Data analysis
All trial analyses will be conducted according to an a
priori statistical analysis plan that will be prepared dur-
ing the early stages of the trial in agreement by the Trial
Management Group, Trial Steering Committee and the
Data Monitoring and Ethics Committee. Primary ana-
lysis will be conducted on the intention-to-treat popula-
tion; however, exploratory analysis may be conducted
excluding patients who do not comply with the protocol.
As the trial is a pragmatic parallel group, the data will
be reported and presented according to the CONSORT
2010 statement [61]. As a feasibility study the main ana-
lysis will be descriptive and focus on confidence interval
estimation and not formal hypothesis testing and will be
guided by the Thabane et al. (2010) checklist for report-
ing of pilot trials [37]. Rates of consent, recruitment and
follow-up by centre and by randomised group will be re-
ported. Outcome measures will be summarised overall
and by randomised group, to inform sample size estima-
tion for the definitive trial. The data from this feasibility
study will be used to estimate the consent rate, attrition
rate and the variability of the continuous outcomes in
the trial population and use this information to inform
the sample size calculation for the definitive RCT. Study
site will be treated as a covariate in an adjusted analysis
where we estimate the treatment effect adjusted for
baseline score and site. Since the intervention is therap-
ist led, the data will be used to estimate the intra-cluster
correlation coefficient for patients treated by the same
therapist using a marginal or random effects model for
the 6-month post-randomisation PHQ-9 outcome.
As part of the feasibility analysis, the effect size for the
6-month PHQ-9 outcome and the difference in mean
scores (and associated 95 % confidence intervals [62])
between groups will be estimated. A marginal or random
effects model will be used to allow for any clustering by
therapist, with baseline PHQ-9 as a covariate to check
that the likely effect is within a clinically relevant range,
and this will be used as confirmation that it is worth
progressing with the definitive trial. The accuracy of the
cut-off of the VAMS Sad in comparison with the PHQ-9
will also be checked. This information along with the
acceptability of the study design and protocol to patients
and carers; the safety of the intervention; patient recruit-
ment and consent/retention rates will enable us to deter-
mine whether or not the definitive RCT is feasible.
Health economic analysis
For the health economic analysis a cost-utility analysis will
be undertaken from the NHS and personal social service
perspective. Due to the importance of carers for patients
with post-stroke depression, a supplementary analysis will
be undertaken, taking a societal perspective. Costs and
utilities will be estimated for individual patients using data
collected at baseline and follow-up, based upon responses
to EQ5D and resource use questionnaires, combined with
standard cost and valuation sources [63–65]. Costs will
include intervention costs and health care resource use.
Questionnaires will be tested as a method for collecting
resource use data and information on carer time.
Participants who do not have moderate or severe lan-
guage problems will be asked to complete the standard
version of the EQ5D as well as an amended picture-based
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version that is intended to be accessible to people with
aphasia. This has not been validated but has been used in
studies with similar patient populations [60, 66, 67]. Partici-
pants who do have moderate to severe language problems
will be asked to complete the accessible version of the
EQ5D. In addition, for participants who have carers, the
carer will be asked to complete a standard EQ5D by proxy
[60]. This will allow us to test alternative methods for
collecting data from which to calculate quality-adjusted life
years (QALYs) relevant for the patients included in the
study. Utility scores based upon EQ5D responses will be
calculated for patients at baseline and follow-up and QALYs
will be calculated using the area under the curve defined by
the scores and straight line interpolation.
Differences between costs and QALYs in the two groups
will be described and the incremental cost-effectiveness
ratio will be calculated. A trial-based analysis will be
supplemented by an analysis using a simple decision ana-
lytic model, which will be used to estimate the cost-
effectiveness of the intervention over the lifetime of the
patients. This will be populated using the trial data plus
information from the literature where required. Whilst
this analysis will allow the estimation of lifetime cost-
effectiveness and associated cost-effectiveness accept-
ability curves through the use of probabilistic sensitivity
analysis, it is recognised that this will represent only a
provisional estimate of the potential cost-effectiveness of
the intervention, due to the nature of the feasibility study.
The key outcome from the economic evaluation will be
provided by a value of information analysis which will
allow us to identify those model parameters that are the
best candidates for further research [68]. This will be done
by estimating expected values of perfect information for
each parameter, which in essence identifies the maximum
return for additional research [69].
Qualitative data analysis
The qualitative data will be analysed thematically, using a
framework analysis approach [70] to allow us to explore
both a priori and emergent themes across the dataset. The
transcripts from the patient and carer interviews will be
explored to understand their experiences of being re-
cruited into the trial, the study procedures and for those
in the intervention group, their experiences of the BA
therapy, acceptability and any perceived impacts or bene-
fits. The transcripts of the interviews with the therapists
will be examined to understand the feasibility and accept-
ability of the study and intervention procedures in more
depth, with a view to informing the design of any future
trial and subsequent intervention.
Anticipated risks and benefits
This study is not an investigation of a medicinal product
and entails no invasive procedures. The benefits of BA
suggested by the CALM trial include improved mood
[33]. No participants will have any existing treatments
withdrawn. The intervention is low risk to the trial partici-
pants however, and stopping on grounds of patient safety is
not anticipated. As this is a feasibility trial, it will not stop
early for efficacy. The study may be stopped as a whole be-
cause of safety concerns or issues with study conduct at the
discretion of the sponsor. There are no formal statistical
criteria for stopping the trial early. Decisions to stop the
trial early on grounds of safety or futility will be made by
the Trial Steering Committee (TSC) on the basis of advice
from the Data Monitoring and Ethics Committee (DMEC).
There is a risk that participants may experience some
distress from being asked about their mood, but all
researchers and therapists will be trained to deal with
these situations. If at any point during the baseline assess-
ment, intervention or outcome assessment the researcher
or therapist is concerned about a participant, for example,
severe distress or reporting feeling suicidal, then the
necessary referrals will be made.
Suicide and suicidal intentions
The risks of suicide are inherent in the nature of the
condition under scrutiny (depression), and for the pur-
poses of this study are classed as adverse events. We will
follow good clinical practice in monitoring for suicide
risk during all encounters with trial participants. Where
any risk to patients due to expressed thoughts of suicide
is encountered, we will follow local suicide protocols for
each participating site.
Data management
The case report form (CRF) will be used to record de-
tails at all stages of the study. CRF data will be entered
at participating sites by trial staff onto an online data-
base developed and managed by the Sheffield Clinical
Trials Research Unit. Data will be stored in line with
standard operating procedures. In order to help ensure
good data quality, validation checks will be applied at
point of entry, and comprehensive post-entry validation
reports will be run regularly to generate discrepancies
for site staff to investigate. Additionally, a sample of
paper CRF records will be verified against the database
data to identify any data entry issues.
Site monitoring
Site monitoring will be completed before, during and after
the trial to monitor trial data quality. For example, con-
firmation of informed consent; source data verification
(review of paper CRFs against source data); data entry
verification (review of database records against paper
CRFs); data storage and data transfer procedures; local
quality control checks and procedures. Entries on CRFs
will be verified by inspection against the source data. A
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sample of CRFs (at least 10 %) will be checked on a regu-
lar basis for verification of all entries made. In addition,
the subsequent capture of the data on the trial database
will be checked. Where corrections are required these will
carry a full audit trail and justification.
Publication and dissemination policy
We will disseminate findings in peer-reviewed scientific
journals and clinical and academic conferences, both
national and international. A final report and monograph
will be produced for the funder (National Institute for
Health Research Health Technology Assessment). We will
ensure regular dissemination to interested parties via the
study website or mailing lists. A lay summary of findings
for participants, service users and carers that is accessible
to stroke survivors will be produced in consultation with
the PPI group. An executive summary will be prepared for
the Trusts where the research was conducted.
User and public involvement
A Public and Patient Involvement group has been formed
for the study and will have input at the planning, conduct,
analysis and dissemination stages of the study. A plain
English summary of study progress will be provided to the
group every 6 months and they will meet at regular inter-
vals throughout the study. Information materials for partic-
ipants will be developed in consultation with the group to
ensure they are appropriate and accessible. Involvement
will also include advice on considerations of how best to
deliver the intervention to the stroke population, from the
service users’ perspective; contributing to ideas on recruit-
ment strategies. This group will also advise on the dissem-
ination materials.
Trial management
Three committees have been established to govern the
conduct of the study: the Trial Steering Committee (TSC),
Data Monitoring and Ethics Committee (DMEC) and the
Trial Management Group (TMG). The TSC will consist of
an independent chair with clinical and research expertise
in the topic area and three other topic experts. The TSC
will meet at least every 6 months to supervise the overall
conduct of the trial. The DMEC will consist of an inde-
pendent chair with clinical and research expertise in the
topic area, and two other topic experts, plus an independ-
ent medical statistician. The role of the DMEC is to review
serious adverse events thought to be treatment-related
and look at outcome data regularly during data collection.
They will meet at least annually.
Discussion
This pilot trial is designed to assess the feasibility of a de-
finitive multicentre RCT to evaluate the clinical and cost-
effectiveness of BA for treating post-stroke depression.
Ethical approval was obtained on 29 January 2015. Re-
cruitment to BEADS started in May 2015 and is planned
to run until the end of April 2016.
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